MDWD250117P14000
- 0.10
- 0.000.00%
MediWound Newsroom
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)
Buy Rating for Mediwound Driven by EscharEx's Market Potential and Disruptive Role in Chronic Wound Care
Citi Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $25
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound (MDWD) Receives a Buy From TD Cowen
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30
Strategic Growth and Market Potential Drive Buy Rating for MediWound Despite Revenue Decline
MediWound Analyst Ratings
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $25
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
MediWound Analyst Ratings
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $30
Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
MediWound Analyst Ratings